17485422

Source:http://linkedlifedata.com/resource/pubmed/id/17485422

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003873, umls-concept:C0008976, umls-concept:C0021760, umls-concept:C0043309, umls-concept:C0205177, umls-concept:C0205210, umls-concept:C0332120, umls-concept:C0814225, umls-concept:C1609165, umls-concept:C1999216, umls-concept:C2587213, umls-concept:C2603343
pubmed:issue	9
pubmed:dateCreated	2007-8-13
pubmed:abstractText	To evaluate the ability of tocilizumab (a humanised anti-IL-6 receptor antibody) monotherapy to inhibit progression of structural joint damage in patients with RA.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372355
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6, http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate, http://linkedlifedata.com/resource/pubmed/chemical/tocilizumab
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	0003-4967
pubmed:author	pubmed-author:HashimotoJunJ, pubmed-author:KawaiShinichiS, pubmed-author:KishimotoTadamitsuT, pubmed-author:MiyasakaNobuyukiN, pubmed-author:MurataNorikazuN, pubmed-author:NishimotoNorihiroN, pubmed-author:TakeuchiTsutomuT, pubmed-author:YamamotoKazuhikoK, pubmed-author:van der HeijdeDésiréeD
pubmed:issnType	Print
pubmed:volume	66
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1162-7
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:17485422-Adult, pubmed-meshheading:17485422-Aged, pubmed-meshheading:17485422-Analysis of Variance, pubmed-meshheading:17485422-Antibodies, Monoclonal, pubmed-meshheading:17485422-Antibodies, Monoclonal, Humanized, pubmed-meshheading:17485422-Antirheumatic Agents, pubmed-meshheading:17485422-Arthritis, Rheumatoid, pubmed-meshheading:17485422-Bacterial Infections, pubmed-meshheading:17485422-Disease Progression, pubmed-meshheading:17485422-Double-Blind Method, pubmed-meshheading:17485422-Female, pubmed-meshheading:17485422-Foot Joints, pubmed-meshheading:17485422-Hand Joints, pubmed-meshheading:17485422-Humans, pubmed-meshheading:17485422-Interleukin-6, pubmed-meshheading:17485422-Male, pubmed-meshheading:17485422-Methotrexate, pubmed-meshheading:17485422-Middle Aged, pubmed-meshheading:17485422-Severity of Illness Index, pubmed-meshheading:17485422-Treatment Outcome
pubmed:year	2007
pubmed:articleTitle	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
pubmed:affiliation	Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University 1-3, Yamada-oka, Suita, Osaka, 565-0871, Japan. norihiro@fbs.osaka-u.ac.jp
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study